Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Harpoon Therapeutics, Inc. (HARP) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/09/2023 8-K Quarterly results
Docs: "Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update"
03/31/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/27/2023 8-K Quarterly results
12/12/2022 8-K Quarterly results
12/01/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
09/19/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/10/2022 8-K Quarterly results
06/28/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/10/2022 8-K Quarterly results
01/11/2022 8-K Investor presentation
Docs: "Spearheading Immunotherapies Investor Presentation, dated January 2022"
12/13/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., November 10, 2021"
10/26/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/05/2021 8-K Quarterly results
Docs: "Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Presented updated interim Phase 1/2a clinical trial data for PSMA-targeting TriTAC® HPN424 in prostate cancer at ASCO Annual Meeting Provided clinical trial updates for three additional TriTAC programs and ProTriTAC platform"
06/04/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/26/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
01/07/2021 8-K Quarterly results
01/04/2021 8-K Quarterly results
12/11/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Risk Factors",
"Risk Factors"
12/09/2020 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 8, 2020 Harpoon Therapeutics, Inc. Delaware 001-38800 47-3458693 131 Oyster Point Blvd, Suite 300 South San Francisco, California 94080 443-7400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communicat...",
"Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC ® Pipeline Development Programs",
"Clinical Pipeline Update Presentation"
11/04/2020 8-K Quarterly results
Docs: "Harpoon Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update"
08/05/2020 8-K Quarterly results
07/02/2020 8-K Quarterly results
06/01/2020 8-K Submission of Matters to a Vote of Security Holders
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 28, 2020 Harpoon Therapeutics, Inc. Delaware 001-38800 47-3458693 131 Oyster Point Blvd, Suite 300 South San Francisco, California 94080 443-7400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications..."
05/29/2020 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 29, 2020 Harpoon Therapeutics, Inc. Delaware 001-38800 47-3458693 131 Oyster Point Blvd, Suite 300 South San Francisco, California 94080 443-7400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications...",
"Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC ® HPN424 at the ASCO20 Virtual Scientific Program",
"Phase 1 HPN424 Interim Data Presentation and Pipeline Update"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy